GlassScriptPhysician profile
Ivo Teneng
NPI 1548768450
$2,526.80
in general payments reported to CMS, 2019-2025
35 companies · $938 in 2025
The $938 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $282 · 2023: $595 · 2024: $712 · 2025: $938.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,245.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,244.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $345.33 | 2023-2025 | |
| Abbvie INC. | $342.08 | 2022-2025 | |
| Sobi, INC | $210.43 | 2024-2025 | |
| Karyopharm Therapeutics INC. | $170.34 | 2023-2025 | Xpovio |
| Celgene Corporation | $129.83 | 2022-2025 | Pomalyst, Opdivo |
| Incyte Corporation | $126.92 | 2022-2025 | Jakafi, Niktimvo |
| Gilead Sciences, INC. | $122.35 | 2023-2025 | Trodelvy |
| Exelixis INC. | $108.49 | 2022-2025 | Cabometyx |
| Mirati Therapeutics, INC. | $76.26 | 2023-2024 | Krazati |
| Morphosys, US INC. | $67.77 | 2022-2024 | Monjuvi |
| Genmab U.S., INC. | $65.53 | 2025 | Epkinly |
| Pharmacyclics LLC, An Abbvie Company | $61.54 | 2023 | Epkinly |
| Astrazeneca Pharmaceuticals LP | $56.95 | 2023-2024 | |
| Daiichi Sankyo INC. | $48.63 | 2024-2025 | Enhertu, Vanflyta |
| Coherus Oncology, INC. | $45.97 | 2024 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Adc Therapeutics America, INC. | $45.70 | 2023-2024 | |
| Recordati_rare_diseases_inc. | $45.18 | 2023-2024 | Sylvant |
| G1 Therapeutics, INC. | $43.56 | 2022 | |
| Alexion Pharmaceuticals, INC. | $39.92 | 2023 | Ultomiris |
| Amgen INC. | $31.61 | 2022-2023 | Lumakras |
| Alnylam Pharmaceuticals INC. | $27.99 | 2023 | Givlaari |
| Geron Corporation | $26.36 | 2025 | Rytelo |
| Tersera Therapeutics LLC | $26.19 | 2023 | Xermelo |
| Glaxosmithkline, LLC. | $24.87 | 2022 | |
| Fennec Pharmaceuticals, INC. | $24.67 | 2025 | Fyarro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.48 | 2025 | |
| Immunogen, INC. | $23.27 | 2023 | Elahere |
| Rigel Pharmaceuticals, INC. | $22.91 | 2023 | Rezlidhia, Tavalisse |
| Sanofi-Aventis U.S. LLC | $22.56 | 2022 | |
| Beone Medicines USA, INC. | $22.02 | 2025 | Tevimbra |
| E.R. Squibb & Sons, L.L.C. | $21.09 | 2022 | |
| Aveo Pharmaceuticals, INC. | $19.44 | 2025 | |
| Btg International INC. | $19.17 | 2025 | Voraxaze |
| Ipsen Biopharmaceuticals, INC | $18.80 | 2022 | |
| Cti Biopharma Corp. | $18.59 | 2023 | Vonjo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ivo Teneng listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.